Celldex Therapeutics (FRA:TCE2) Cyclically Adjusted FCF per Share: €-5.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TCE2 Celldex Therapeutics Inc FRA:TCE2
62 GF Score
Price €32.93
GF Value €7.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Cyclically Adjusted FCF per Share?

Celldex Therapeutics FRA:TCE2 +0.15% 62 Cyclically Adjusted FCF per Share is €-5.03 as of Mar. 2026. GuruFocus rates FRA:TCE2 with a GF Score™ of 62/100 and a GF Value™ of €7.05 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Celldex Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.874. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-5.03 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 15.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Celldex Therapeutics was 28.80% per year. The lowest was -9.90% per year. And the median was 6.80% per year.

As of today (2026-07-17), Celldex Therapeutics's current stock price is €32.93. Celldex Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-5.03. Celldex Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Celldex Therapeutics  (FRA:TCE2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Celldex Therapeutics Cyclically Adjusted FCF per Share Related Terms


Celldex Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Cyclically Adjusted FCF per Share Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.61 -10.58 -9.23 -8.04 -5.47

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.83 -6.40 -5.92 -5.47 -5.03

FRA:TCE2 vs TARS, KLRA, IRON: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:TCE2
62GF Score
Celldex Therapeutics Inc FRA:TCE2
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.874/330.2130*330.2130
=-0.874

Current CPI (Mar. 2026) = 330.2130.

Celldex Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -4.674 241.018 -6.404
201609 -3.287 241.428 -4.496
201612 -2.765 241.432 -3.782
201703 -4.075 243.801 -5.519
201706 -2.317 244.955 -3.123
201709 -2.392 246.819 -3.200
201712 -1.829 246.524 -2.450
201803 -2.448 249.554 -3.239
201806 -1.544 251.989 -2.023
201809 -1.135 252.439 -1.485
201812 -1.177 251.233 -1.547
201903 -0.966 254.202 -1.255
201906 -0.719 256.143 -0.927
201909 -0.670 256.759 -0.862
201912 -0.607 256.974 -0.780
202003 -0.642 258.115 -0.821
202006 -0.488 257.797 -0.625
202009 -0.260 260.280 -0.330
202012 -0.113 260.474 -0.143
202103 -0.395 264.877 -0.492
202106 -0.253 271.696 -0.307
202109 -0.310 274.310 -0.373
202112 -0.282 278.802 -0.334
202203 -0.488 287.504 -0.560
202206 -0.464 296.311 -0.517
202209 -0.765 296.808 -0.851
202212 -0.441 296.797 -0.491
202303 -0.577 301.836 -0.631
202306 -0.539 305.109 -0.583
202309 -0.380 307.789 -0.408
202312 -0.585 306.746 -0.630
202403 -0.640 312.332 -0.677
202406 -0.417 314.175 -0.438
202409 -0.759 315.301 -0.795
202412 -0.478 315.605 -0.500
202503 -0.761 319.799 -0.786
202506 -0.584 322.561 -0.598
202509 -0.629 324.800 -0.639
202512 -0.838 324.054 -0.854
202603 -0.874 330.213 -0.874

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-5.03 mean?
Celldex Therapeutics (FRA:TCE2) has a Cyclically Adjusted FCF per Share of €-5.03 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Cyclically Adjusted FCF per Share too high?
Celldex Therapeutics' current Cyclically Adjusted FCF per Share is €-5.03. Overall, Celldex Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Cyclically Adjusted FCF per Share compare to TARS and KLRA?
Celldex Therapeutics' Cyclically Adjusted FCF per Share of €-5.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Cyclically Adjusted FCF per Share is €-5.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (FRA:TCE2) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.05, compared to a current price of €32.93 — trading 367.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-5.03. Celldex Therapeutics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Celldex Therapeutics (FRA:TCE2), the current Cyclically Adjusted FCF per Share is €-5.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (FRA:TCE2) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of €32.93 is trading 367.1% above its estimated GF Value™ of €7.05. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:TCE2:

  • Cyclically Adjusted FCF per Share: €-5.03
  • GF Value™: €7.05 vs. price of €32.93 (367.1% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the FRA:TCE2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges CLDX:USA
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
62GF Score

Get the complete analysis for FRA:TCE2

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.93
Price
€7.05
GF Value